Oncology Corporate Profile
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk in a variety of cancer types. Stemline is currently developing two clinical-stage product candidates, SL-401 and SL-701.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|SL-401||interleukin-3 receptor (IL-3R)||Acute Myelogenous Leukemia (AML)||II|
|SL-701 (+ immunostimulant and bevacizumab)||immunotherapy||Glioblastoma Multiforme (GBM)||I|
|SL-801||XPO1 inhibitor||Various cancer types||I|